Otsuka Wins FDA Approval for First-in-Class SIMTRIYO for ADHD
PRINCETON, N.J. and TOKYO, Japan, July 24, 2026 Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd....
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
PRINCETON, N.J. and TOKYO, Japan, July 24, 2026 Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd....
GRÄFELFING, Germany – June 9, 2026 VERTANICAL has achieved a major milestone in chronic pain treatment after receiving Germany’s...
TORONTO, Ontario, Canada, April 7, 2026 Apotex Inc., a leading global pharmaceutical company, announced that Health Canada has approved...
NEW HAVEN, Conn., USA — April 1, 2026 BioXcel Therapeutics, Inc. announced that the U.S. Food and Drug Administration...
WASHINGTON, D.C. — December 15, 2025 — LIB Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA)...
EAST HANOVER, N.J., Sept. 30, 2025 – Novartis today announced that the U.S. Food and Drug Administration (FDA) has...
